ERBB2 and neoplasm: From a clinical standpoint, a significant drawback of conventional methods fordetermining the HER2/ neu status at the diagnostic stage is the impossibilityto simultaneously assess tumor progression in vivo and analyzethe molecular characteristics of identified tumor lesions prior to theadministration of a specific treatment [29].